FDA Delays Decision on Savara’s Molgramostim for Autoimmune PAP

Share on Social Media

Savara's investigational molgramostim inhalation therapy for autoimmune pulmonary alveolar proteinosis faces an extended FDA review.
Image: Pexels

The FDA will miss the November 22 PDUFA date for Savara’s molgramostim BLA in autoimmune PAP, extending regulatory uncertainty without a revised action date.

Written By: Creola Gonsalves, MS Biotech

Reviewed By: Pharmacally Editorial Team

Savara reported that the US Food and Drug Administration (FDA) will not meet the November 22, 2026, Prescription Drug User Fee Act (PDUFA) target action date for its Biologics License Application (BLA) covering molgramostim inhalation solution for autoimmune pulmonary alveolar proteinosis (autoimmune PAP). The agency informed the company that its review remains ongoing but has not provided a revised action date.

The latest delay introduces further uncertainty into the regulatory timeline for molgramostim, an investigational inhaled recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF). Although the FDA previously extended the review period by three months in April 2026, the reason for the latest missed deadline has not been disclosed.

FDA Review Continues After Earlier Three-Month Extension

The November 22, 2026, PDUFA date was already a revised deadline following an earlier FDA extension announced on April 15, 2026. At that time, the agency determined that Savara’s responses to information requests constituted a major amendment to the BLA, requiring an additional three months to complete its Priority Review.

The FDA did not identify safety, efficacy or manufacturing concerns in its April correspondence. However, the company has not disclosed whether the latest delay reflects additional information requests, outstanding regulatory questions or other considerations within the ongoing assessment.

The FDA informed Savara that the review remains ongoing but has not provided a revised action date. The company’s Chairman and Chief Executive Officer, Matt Pauls, said Savara appreciates the agency’s continued efforts and intends to work closely with regulators to complete the review.

The BLA is supported by results from the pivotal Phase 3 IMPALA-2 trial (NCT04544293), which enrolled 164 adults with autoimmune PAP. Molgramostim 300 µg administered once daily by inhalation achieved its primary endpoint, demonstrating a statistically significant improvement in hemoglobin-adjusted percent-predicted diffusing capacity of the lungs for carbon monoxide (DLCO) compared with placebo at Week 24 (treatment difference: 6.0 percentage points; p=0.0007). The improvement was sustained at Week 48, with a treatment difference of 6.9 percentage points (p=0.0008).

Molgramostim has also received FDA Priority Review, Breakthrough Therapy, Fast Track and Orphan Drug designations for autoimmune PAP.

Autoimmune PAP: GM-CSF Dysfunction Impairs Surfactant Clearance

Autoimmune PAP is a rare lung disease characterized by the accumulation of pulmonary surfactant within the alveoli, the small air sacs responsible for oxygen and carbon dioxide exchange.

Under normal conditions, alveolar macrophages clear excess surfactant and maintain pulmonary function. GM-CSF plays an essential role in regulating the maturation and activity of these immune cells.

In autoimmune PAP, patients develop autoantibodies that neutralize endogenous GM-CSF, disrupting alveolar macrophage function and impairing surfactant clearance. The resulting accumulation interferes with pulmonary gas exchange and can cause breathlessness, persistent cough and fatigue. Patients may also develop recurrent respiratory infections, while advanced disease can lead to pulmonary fibrosis, respiratory failure and, in severe cases, lung transplantation.

Molgramostim Targets the Underlying Biological Dysfunction

Molgramostim is an investigational recombinant human GM-CSF administered directly to the lungs through an investigational eFlow Nebulizer System developed by PARI Pharma GmbH.

By delivering GM-CSF locally, molgramostim is intended to restore GM-CSF signalling in alveolar macrophages, improve their surfactant-clearance function and address the underlying pathophysiology of autoimmune PAP.

Currently, no pharmacological therapy has received FDA approval specifically for autoimmune PAP. Treatment options include whole-lung lavage (WLL), an invasive procedure performed under general anesthesia to remove accumulated surfactant, and inhaled GM-CSF therapy. The European Respiratory Society recommends both approaches as first-line treatment options for symptomatic patients.

Unlike WLL, which physically removes accumulated surfactant, molgramostim is being developed to restore the biological mechanism responsible for its clearance.

Regulatory Outlook

The FDA’s latest delay leaves the timing of a potential US marketing authorization uncertain. The agency has not provided a revised PDUFA date, and Savara has not disclosed when it expects to receive further regulatory guidance.

The ongoing review will determine whether molgramostim can become the first FDA-approved pharmacological therapy specifically for autoimmune PAP. Until the agency completes its assessment, the treatment remains investigational.

Molgramostim’s safety and efficacy have not been established by the FDA or any other regulatory authority, and it is not currently approved for use in autoimmune PAP.

Reference

Savara Informed That FDA Will Not Take Action on the Molgramostim BLA for Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) by the PDUFA Date, Savara, 20 November 2026

Clinical Trial of Inhaled Molgramostim Nebulizer Solution in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) (IMPALA-2), ClinicalTrials.gov ID NCT04544293

About the Writer

Creola Gonsalves (Linkedin) is an M.S. Biotechnology postgraduate with a strong interest in clinical research, evidence interpretation, and healthcare writing, with a focus on translating life-science knowledge into meaningful real-world insights.
She is trained in Good Clinical Practice (GCP), clinical research principles, and critical interpretation of randomized clinical trials, with certifications from NIH and Stanford University.
Her research background in biotechnological applications and microbial research strengthens her ability to understand scientific evidence and develop clear, accurate, and research-driven healthcare content.


Share on Social Media
Scroll to Top